Markets:

Overview

News

Currencies

International

Treasuries

Innovent Biologics Inc (OP:IVBXF)

11.24 +0.18 (+1.63%)

Delayed Quote Updated: 2:35 PM EST, Nov 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Innovent Biologics Inc

< Previous 1 2 Next >

Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer. ↗

June 06, 2026

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Via The Motley Fool

Topics Intellectual Property

Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal ↗

August 24, 2024

Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with...

Via Talk Markets

Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal ↗

July 27, 2024

Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus...

Via Talk Markets

Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma ↗

July 06, 2024

Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was...

Via Talk Markets

Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China ↗

August 04, 2022

Via Benzinga

Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary ↗

June 30, 2024

Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to...

Via Talk Markets

Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings ↗

May 25, 2024

Via Talk Markets

Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals ↗

May 11, 2024

Beijing’s Sino Biological completed its $48 million acquisition of Vancouver-based SignalChem Biotech. Additionally, Biocytogen Pharmaceuticals signed a TCR-mimic antibody evaluation and potential...

Via Talk Markets

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗

March 23, 2024

Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.

Via Talk Markets

Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform ↗

March 09, 2024

Shenzhen EurekaBio closed a $40 Series B+ funding to support the commercialization of its EuLV Lentiviral Vector Production System, a technology that the company believes could transform large-scale...

Via Talk Markets

Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal ↗

March 02, 2024

Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...

Via Talk Markets

Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership ↗

February 24, 2024

Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody...

Via Talk Markets

Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million ↗

February 11, 2024

I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China...

Via Talk Markets

Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal ↗

December 31, 2023

Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program....

Via Talk Markets

Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments ↗

December 02, 2023

LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...

Via Talk Markets

Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion ↗

November 04, 2023

Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have...

Via Talk Markets

Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca ↗

August 26, 2023

China’s drug distributors are in the hunt to acquire Poland’s Neuca, a company with a 32% market share of Poland’s pharmaceutical distribution business. The consortium of China’s drug distributors may...

Via Talk Markets

Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration ↗

July 08, 2023

F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...

Via Talk Markets

Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront ↗

July 01, 2023

Via Talk Markets

Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas ↗

June 17, 2023

Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates...

Via Talk Markets

Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO ↗

June 10, 2023

HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and...

Via Talk Markets

Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC ↗

May 13, 2023

Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....

Via Talk Markets

Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion ↗

February 18, 2023

Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of...

Via Talk Markets

Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development ↗

February 04, 2023

Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a...

Via Talk Markets

Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific ↗

December 17, 2022

Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will...

Via Talk Markets

Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact ↗

December 10, 2022

In a blockbuster agreement, Guangzhou’s Akeso out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion. Summit Therapeutics will pay $500 million upfront and...

Via Talk Markets

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting ↗

March 24, 2022

The

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.